Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00909350 · ClinicalTrials.gov registry record
Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue
A clinical trial of Esophageal Adenocarcinoma and Barrett's Esophagus, sponsored by Mayo Clinic.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT00909350 is a study of Esophageal Adenocarcinoma and Barrett's Esophagus that has completed, run by Mayo Clinic. The registered enrollment target is 10 participants, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00909350, a study of Esophageal Adenocarcinoma and Barrett's Esophagus, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a laboratory-based, exploratory study using tissue obtained from our clinical practice. The purpose of this study is to confirm our ability to characterize miR expression in various tissues (proximal and distal esophagus, stomach and duodenum) obtained from the upper gastrointestinal tract in preparation for the study of MiR in patients with Barrett's esophagus and other inflammatory conditions of the upper gastrointestinal tract.
Conditions Studied
Study Locations (1)
Florida
- Mayo Clinic - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00909350
The ClinicalTrials.gov registry entry for NCT00909350 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (97% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT00909350 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00909350 about?
NCT00909350 is a clinical study titled "Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue". This is a laboratory-based, exploratory study using tissue obtained from our clinical practice. The purpose of this study is to confirm our ability to characterize miR expression in various tissues (proximal and distal esophagus, stomach and duodenum) obtained from the upper gastrointestinal tract i...
What is the current status of trial NCT00909350?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2008-04. Estimated completion is 2008-11.
What conditions does trial NCT00909350 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Barrett's Esophagus.
Who is sponsoring clinical trial NCT00909350?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00909350 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
RECRUITING
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.